To define the specific contribution of selected macrophage subsets, we took advantage of the well-established slow recovery rate of SIGN-R1 macrophages after CLL treatment to study a time window in which SIGN-R1+MARCO+ cells are missing but both SIGN-R1−MARCO+ and CD169+ cells have recovered (7). This evidence concerns the gene SIGLEC1 and B-cell chronic lymphocytic leukemia.